Natixis’s Caris Life Sciences CAI Stock Holding History

Natixis’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.22M	Buy	124,716 +71,938	+136%	+$1.29M	0.01%	613
2026 Q1	$944K	Buy	+52,778	New	+$1.15M	﹤0.01%	700

Other funds holding CAI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHWEPV

J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

SSP

Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Natixis's CAI Position: Q2 2026 in Review

Natixis increased its Caris Life Sciences (CAI) stake by 136% in Q2 2026, buying an estimated $1.29M and bringing the position to 124,716 shares worth $2.22M. The position accounts for 0.01% of the portfolio, ranked #613.

Natixis first reported a position in CAI in Q1 2026 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

Natixis held 124,716 shares of Caris Life Sciences worth $2.22M as of Q2 2026.
Natixis bought 71,938 Caris Life Sciences shares in Q2 2026, an estimated $1.29M.
Caris Life Sciences made up 0.01% of Natixis's portfolio in Q2 2026, its #613 holding.
Natixis first reported a position in Caris Life Sciences in Q1 2026 and has held it in 2 quarters since.
246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.